Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
0.6457
-0.0243 (-3.63%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

Biodesix, Inc. operates as a diagnostic solutions company.

The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, together marketed as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions.

In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies.

The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006.

Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Biodesix, Inc.
Biodesix logo
Country United States
Founded 2005
IPO Date Oct 28, 2020
Industry Diagnostics & Research
Sector Healthcare
Employees 273
CEO Scott Hutton

Contact Details

Address:
919 West Dillon Road
Louisville, Colorado 80027
United States
Phone 303 417 0500
Website biodesix.com

Stock Details

Ticker Symbol BDSX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001439725
CUSIP Number 09075X108
ISIN Number US09075X1081
Employer ID 20-3986492
SIC Code 8071

Key Executives

Name Position
Scott Hutton President, Chief Executive Officer and Director
Robin Harper Cowie Chief Financial Officer, Secretary and Treasurer
Kieran O'Kane Chief Commercial Officer
Dr. Heinrich Röder Founder and Chief Technology Officer
Jessica Olbricht Senior Director of Human Resources
Dr. Gary Anthony Pestano Ph.D. Chief Development Officer
Bobbi Coffin Chief Growth Officer
Dr. James R. Jett M.D. Co-Chief Medical Officer
Dr. Steven C. Springmeyer Co-Chief Medical Officer
Christopher Vazquez Vice President and Controller

Latest SEC Filings

Date Type Title
Mar 28, 2025 8-K Current Report
Mar 3, 2025 10-K Annual Report
Mar 3, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 11, 2025 144 Filing
Feb 11, 2025 144 Filing
Feb 11, 2025 144 Filing
Feb 11, 2025 144 Filing
Feb 7, 2025 S-8 Securities to be offered to employees in employee benefit plans
Jan 10, 2025 8-K Current Report